Additionally, we have explored emerging TK1-targeted therapeutic modalities, including gene-directed enzyme prodrug therapy (GDEPT), nanoscale drug delivery platforms, and adoptive cell therapy, while evaluating TK1's translational potential in GC management. Here, TK1 is linked to gastric cancer.